華西證券(002926.SZ):公司零售財富業務在川內市場佔比較高
格隆匯7月25日丨有投資者向華西證券(002926.SZ)提問:公司零售業務開展情況、在川內市場地位以及公司省內外營業部數量及分佈情況?
華西證券回覆:零售財富業務一直以來都是公司的主要收入來源,發揮着“壓艙石”的作用。公司零售財富業務2022年實現淨收入28.7億元,利潤12.6億元,保持了前20位的行業排名。經過長期耕耘與積累,公司零售財富業務在川內市場佔比較高,也具有較高的客户粘性。公司在不斷鞏固川內市場的同時也積極佈局全國,特別是加大京津冀、長三角、珠三角等重點區域投入。截至目前,公司共設有116家證券營業部,其中四川省內57家,省外59家,此外公司還設有24家分公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.